Working... Menu

Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Patients With Stage I-II HER2/Neu Positive Breast Cancer After Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02654119
Recruitment Status : Recruiting
First Posted : January 13, 2016
Last Update Posted : October 22, 2018
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Pavankumar Tandra MD, University of Nebraska

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : November 20, 2025
  Estimated Study Completion Date : November 20, 2026